Survival difference between EGFR exon 19 deletion and exon 21 mutation in advanced non-small cell lung cancer patients

被引：1
|
作者：
Guardiario, Dawn Lynn P. [1 ]
Cornelio, Gerardo H. [1 ]
Marave, Raiza S. [1 ]
机构：
[1] St Lukes Med Ctr, Sect Med Oncol, Quezon City, Philippines
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.05.273
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P28-10
引用
收藏
页码：S523 / S523
页数：1
相关论文
共 50 条
  • [1] Is exon 19 deletion different from exon 21 mutation in advanced non-small cell lung cancer: A single centre experience
    Shrivastva, S.
    Stalin, B.
    Gundeti, S.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [2] EGFR Exon 19 Deletion Mutation Patients Obtain Optimal Survival in Icotinib Treated Non-Small Cell Lung Cancer Patient with Brain Metastases
    Xu, Xiaoling
    Zhao, An
    Zheng, Lei
    Mao, Wei-Mao
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) : S311 - S311
  • [3] Association between EGFR exon 19 or exon 21 mutations and survival rates after first-line EGFR-TKI treatment in patients with non-small cell lung cancer
    Jiang, Haiying
    Zhu, Mei
    Li, Yanfang
    Li, Qian
    [J]. MOLECULAR AND CLINICAL ONCOLOGY, 2019, 11 (03) : 301 - 308
  • [4] The impact of EGFR exon 19 deletion subtypes on clinical outcomes in non-small cell lung cancer
    Zhao, Chao
    Jiang, Tao
    Li, Jiayu
    Wang, Yan
    Su, Chunxia
    Chen, Xiaoxia
    Ren, Shengxiang
    Li, Xuefei
    Zhou, Caicun
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (04) : 1149 - +
  • [5] Distinct Benefit of Overall Survival between Patients with Non-Small-Cell Lung Cancer Harboring EGFR Exon 19 Deletion and Exon 21 L858R Substitution
    Koyama, Nobuyuki
    Watanabe, Yasutaka
    Iwai, Yuki
    Kawamura, Rumi
    Miwa, Chihiro
    Nagai, Yoshiaki
    Hagiwara, Koichi
    Koyama, Shinichiro
    [J]. CHEMOTHERAPY, 2017, 62 (03) : 151 - 158
  • [6] Influence of EGFR exon 19 mutation subtypes on survival outcomes in advanced stage Asian non-small cell lung cancer patients receiving TKI therapy
    Chowbay, B.
    Singh, O.
    Sutiman, N.
    Tan, D. S. W.
    Lim, W. T.
    Tan, E. H.
    [J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 : 32 - 32
  • [7] The comparison of EGFR-TKI failure modes and subsequent management between exon 19 deletion and exon 21 L858R mutation in advanced non-small-cell lung cancer
    Zhang, Yaxiong
    Chen, Gang
    Chen, Xi
    Fang, Wenfeng
    Gao, Fei
    Yang, Yunpeng
    Zhao, Yuanyuan
    Ma, Yuxiang
    Hong, Shaodong
    Zhang, Zhonghan
    Miao, Siyu
    Wu, Manli
    Huang, Xiaodan
    Luo, Youli
    Zhou, Cong
    Gong, Run
    Huang, Yan
    Chen, Likun
    Zhou, Ningning
    Zhao, Hongyun
    Zhang, Li
    [J]. JOURNAL OF CANCER, 2017, 8 (10): : 1865 - 1871
  • [8] Exon 19 Deletion Prolongs Survival in Brain Metastases from Non-Small Cell Lung Cancer
    Li, Hongwei
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S279 - S279
  • [9] The different clinical significance of EGFR mutations in exon 19 and 21 in non-small cell lung cancer patients of China
    Li, M.
    Zhang, Q.
    Liu, L.
    Liu, Z.
    Zhou, L.
    Wang, Z.
    Yue, S.
    Xiong, H.
    Feng, L.
    Lu, S.
    [J]. NEOPLASMA, 2011, 58 (01) : 74 - 81
  • [10] Clinical Differences of EGFR Mutations in Exon 19 and 21 in Clinical Course of Non-Small Cell Lung Cancer Patients
    Jang, Tae Won
    Jung, Maanhong
    Oak, Chul H.
    Nam, Sung J.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S528 - S528
12345